New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.

Kanai, Anthony; Chakrabarty, Basu; Winder, Michael; Hashim, Hashim; Wein, Alan; Abrams, Paul; Fry, Christopher

Kanai, Anthony; Chakrabarty, Basu; Winder, Michael; Hashim, Hashim; Wein, Alan; Abrams, Paul; Fry, Christopher.

Afiliación

Kanai A; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, US.
Chakrabarty B; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, US.
Winder M; School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.
Hashim H; Department of Pharmacology, University of Gothenburg, Gothenburg, SE.
Wein A; Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Abrams P; Desai Sethi Institute of Urology, University of Miami Miller School of Medicine, Miami, Florida, US.
Fry C; Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.

Neurourol Urodyn ; 2023 Nov 02.

Article en En | MEDLINE | ID: mdl-37916442

Palabras clave

benign prostatic enlargement (BPE); benign prostatic obstruction (BPO); detrusor overactivity (DO); inflammation; sGC activators; soluble guanylate cyclase (sGC); therapeutics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurourol Urodyn Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google